rhEGF-Loaded Hydrogel in the Treatment of Chronic Wounds in Patients with Diabetes: Clinical Cases
- PMID: 36005124
- PMCID: PMC9407051
- DOI: 10.3390/gels8080523
rhEGF-Loaded Hydrogel in the Treatment of Chronic Wounds in Patients with Diabetes: Clinical Cases
Abstract
The aim of the study was to evaluate the healing process of chronic wounds treated with carboxymethylcellulose loaded with recombinant human epidermal growth factor in patients with diabetes. The case series consisted of 10 patients treated at the university hospital for 12 weeks. Data were analyzed using SPSS version 22.0. according to the intention to treat the principle, without the loss or exclusion of the participants. The sample consisted of 70% (7/10) males with a mean age of 61.9 years (±9.4); all (100%) had diabetes mellitus and 70% (7/10) had systolic hypertension associated with diabetes mellitus. Sixty percent (6/10) presented lesions of diabetic etiology and 40% (4/10) presented lesions of venous etiology; 70% (7/10) had had lesions for less than 5 years. The mean glycated hemoglobin was 7.8% (±2.7%), while the mean ankle-arm index (AAI) was 0.94 (±0.21). The mean initial area of all wounds was 13.4 cm², and the mean final area was 7.8 cm2, with a reduction rate of 28.9% over the 12 weeks of treatment. The reduction rate of diabetic ulcers was higher (33.4%) than that of venous ulcers (22.1%). Regarding the type of tissue, there was an increase in granulation and epithelialization, and a decrease in slough and the amount of exudate that were statistically significant (p = 0.021). No participant had severe or local adverse events during the study period. Epidermal growth factor was effective in the treatment of chronic wounds, especially diabetic ulcers, resulting in the reduction of the wound area and the improvement of tissue and exudate quality.
Keywords: diabetic foot; epidermal growth factor; leg ulcer; nursing; wound healing.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Effectiveness of a synthetic human recombinant epidermal growth factor in diabetic patients wound healing: Pilot, double-blind, randomized clinical controlled trial.Wound Repair Regen. 2021 Nov;29(6):920-926. doi: 10.1111/wrr.12969. Epub 2021 Sep 25. Wound Repair Regen. 2021. PMID: 34563097 Clinical Trial.
-
Immuno-modulatory effect of local rhEGF treatment during tissue repair in diabetic ulcers.Endocr Connect. 2018 Apr;7(4):584-594. doi: 10.1530/EC-18-0117. Epub 2018 Mar 28. Endocr Connect. 2018. PMID: 29592858 Free PMC article.
-
Poorly designed research does not help clarify the role of hyperbaric oxygen in the treatment of chronic diabetic foot ulcers.Diving Hyperb Med. 2016 Sep;46(3):133-134. Diving Hyperb Med. 2016. PMID: 27723012
-
Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.Health Technol Assess. 2000;4(21):1-237. Health Technol Assess. 2000. PMID: 11074391 Review.
-
Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.Ont Health Technol Assess Ser. 2021 Jun 4;21(7):1-165. eCollection 2021. Ont Health Technol Assess Ser. 2021. PMID: 34211616 Free PMC article.
Cited by
-
Recent advances of the nanocomposite hydrogel as a local drug delivery for diabetic ulcers.Front Bioeng Biotechnol. 2022 Oct 4;10:1039495. doi: 10.3389/fbioe.2022.1039495. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36267448 Free PMC article. Review.
-
Solution Blow Spun Mats with Beaded-Fiber Morphologies as a Drug Delivery System with Potential Use for Skin Wound Dressing.ACS Appl Mater Interfaces. 2025 Apr 23;17(16):23466-23483. doi: 10.1021/acsami.4c16675. Epub 2025 Apr 10. ACS Appl Mater Interfaces. 2025. PMID: 40208007 Free PMC article.
-
Research hotspots and trends in nursing for diabetic foot ulcers: A bibliometric analysis from 2013 to 2023.Heliyon. 2024 Aug 8;10(16):e36009. doi: 10.1016/j.heliyon.2024.e36009. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39224296 Free PMC article. Review.
-
Effectiveness of Epidermal Growth Factor Loaded Carboxymethylcellulose (EGF-CMC) Hydrogel in Biofilm Formation in Wounds of Diabetic Patients: A Randomized Clinical Trial.Gels. 2023 Feb 1;9(2):117. doi: 10.3390/gels9020117. Gels. 2023. PMID: 36826286 Free PMC article.
-
Comparative study of chitosan-based liquid dressing and recombinant human epidermal growth factor on acute limb skin wound healing: A randomized controlled trial.JPRAS Open. 2025 Mar 26;44:379-389. doi: 10.1016/j.jpra.2025.03.018. eCollection 2025 Jun. JPRAS Open. 2025. PMID: 40290458 Free PMC article.
References
-
- Armstrong D.G., Eidt J.F., Berman R.S. Clinical assessment of chronic wounds. Wolters Kluwer Up Date. 2019;1:12–18.
-
- Infinity Pharma Epifactor® Revolução da Regeneração da pele. São Paulo. 2019. [(accessed on 20 April 2022)]. Available online: https://infinitypharma.com.br/wp-content/uploads/2019/12/Epifactor.pdf.
Grants and funding
LinkOut - more resources
Full Text Sources